Intelligencia AI

BioPharmaTrend

back to Directory

Intelligencia AI

Website
https://www.intelligencia.ai/

Founded
2017

Patents
2

Publications
7

Technologies

AI Companies (Drug Discovery)

Intelligencia AI™ leads the way in leveraging proprietary data, biomedical expertise and artificial intelligence (AI) with its patented technology to address significant challenges in the pharmaceutical industry. These challenges include lengthy drug development timelines, excessive costs, and unsustainable return on investment (ROI). Its suite of AI-powered solutions delivers actionable insights crucial in mitigating risks and enhancing decision-making associated with drug development by providing an accurate, unbiased assessment of a drug's probability of success.

Founded in 2017, Intelligencia AI is headquartered in New York, NY, with offices in San Francisco, CA, and Athens, Greece, and employs 110 individuals globally. Visit intelligencia.ai to discover more.

Posts Mentioning This Company

Patented AI Platform Identifies Promising Early-Stage BioPharma Assets and Companies

Fierce competition. Thin pipelines. Patent cliffs. The stakes are sky-high for pharmaceutical companies and investors alike. With biotech firms often going public before generating revenue, valuations hinge on the potential for FDA approval of their assets. Herein lies the power of artificial intelligence (AI): by predicting the likelihood of success …

R&D Platform

1. Intelligencia Portfolio Optimizer: The patented SaaS platform Intelligencia Portfolio Optimizer™ delivers on-demand access to AI-powered insights based on best-in-class, proprietary data. This allows users to assess the probability of technical and regulatory success (PTRS) and phase transition probabilities objectively. Equipped with this knowledge, drug companies confidently make more informed asset, portfolio and licensing decisions.

2. Clinical Development Insights: Advanced benchmark analysis

3. Data and Insights: Comprehensive clinical development and biological data to more precisely build models, advance data science applications, and drive business intelligence.

4. USPTO Patent: The patent titled, “System and Interfaces for Processing and Interacting With Clinical Data,” pertains to the company’s novel techniques for training and leveraging a machine learning (ML) model to predict the likelihood of FDA approval for a particular drug.